After Orphazyme's share price was shaved down around 32 percent on Monday, the firm has somewhat recovered in the stock market on Tuesday.
Around noon on Tuesday the share price rose by roughly 8.5 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Coloplast's climate goals approved by international initiative
The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.
Top news from MedWatch this week
Miss anything?
Device Associate Director/Senior Project Leader 
KLIFO is looking for a Clinical Trial Assistant for our office in Glostrup, Lund or Münich 
Director Regulatory Affairs 
Biomarker Operations Lead 
Senior Teaching Fellow for the BioMedical Design Novo Nordisk Foundation Fellowship Program 
QA Specialist for Product Equipment Qualification 
Senior DMPK Laboratory Technologist 
Global Product Manager - Pulmonology 
Nordic Medical Advisor 
Scientific Writer 
Associate, Regulatory Affairs Life Cycle Management